市场调查报告书
商品编码
1280657
药物警戒市场——按类型(软件、服务(按流程、按活动(自发报告、增强的不良事件报告、队列事件监测)、临床试验阶段、服务提供商、最终用途、预测,2023-2032 年Pharmacovigilance Market-By Type (Software, Service {By Process, By Activity [Spontaneous Reporting, Intensified Adverse Drug Reaction Reporting, Cohort Event Monitoring]}), By Clinical Trial Phase, Service Provider, By End-use, & Forecast, 2023-2032 |
全球药物警戒市场将从 2023 年增长到 2032 年,这得益于对药物警戒不断增长的需求以及对数据驱动洞察力的需求,以确保患者安全,预计将出现显着增长。
此外,随着严格的药品审批监管要求,对新药和创新药的需求不断增加,预计将推动未来十年的市场增长。
药物不良反应 (ADR) 和药物毒性发生率的上升推动了对药物警戒的需求。 由于这些疗法的种类和可用性不断增加,必须密切监测它们的安全性和有效性。 药物警戒对于确保药物的益处超过可能的风险的重要性推动了产品的采用。 此外,全球人口的持续激增和慢性病患病率的上升也推动了对药物安全的需求。 根据疾病预防控制中心的数据,每年约有 877,500 名美国人死于心脏病。
疾病负担的增加以及更多专注于有前途的合作伙伴关係和合併以引领行业的主要市场参与者将有利于市场增长。 例如,2023 年 4 月,德国製药公司 PharmaLex 宣布与澳大利亚和新西兰药物警戒提供商 Cpharm 进行战略合併。 通过这种合作关係,两家公司的目标是在澳大利亚市场提供端到端的解决方案,并扩大他们的医疗服务和客户群。
药物警戒市场在类型、临床试验阶段、服务提供商、最终用途和地区方面存在分歧。
根据临床试验阶段,到 2032 年底,2 期部分预计将达到 4.1 亿美元以上。 将进行第二阶段试验,以评估候选药物在大量患有相关疾病或病症的患者中的安全性和有效性。 全球范围内越来越多的临床试验增加了对强大的药物警戒系统的需求,以在这些试验期间监测和确保患者安全。
就最终用途而言,医疗器械公司细分市场的药物警戒市场价值到 2022 年将超过 25 亿美元。 药物警戒服务提供商为公司提供医疗器械安全概况,从处理和报告单个不良事件到将产品撤出市场作为现场安全纠正措施的一部分。 监管机构越来越关注医疗器械的上市后监督和安全监测,这推动了产品的采用。
预计从 2023 年到 2032 年,亚太地区的药物警戒市场将呈现出惊人的复合年增长率。 这是由于大量的外包机构。 生产力、成本效率和资源共享的提高预计将在未来几年增加区域对药物警戒的需求。 此外,人口基数的扩大以及药物摄入量和医疗保健需求的增加也补充了该地区的市场增长。
Global Pharmacovigilance Market is expected to showcase remarkable growth over 2023-2032, driven by the increasing demand for drug safety monitoring and the need for data-driven insights to ensure patient safety. In addition, increasing demand for new and innovative drugs, in line with stringent regulatory requirements for drug approval, will fuel market growth over the next ten years.
The rising incidence rate of adverse drug reactions (ADR) and drug toxicity is encouraging the demand for pharmacovigilance. The safety and effectiveness of these treatments need to be closely monitored, given their increasing diversity and availability. The importance of pharmacovigilance in ensuring that the advantages of medicines outweigh any possible hazards is pushing product adoption. Moreover, the consistent surge in the global population and increased prevalence of chronic diseases have also propelled the need for drug safety. According to CDC, around 877.500 Americans die of heart strokes each year.
The growing disease burden and the increasing focus of key market players on promising partnerships and mergers to stay ahead in the industry will favor market growth. For instance, in April 2023, PharmaLex, a German pharmaceutical firm, announced a strategic merger with Cpharm, a pharmacovigilance provider in Australia and New Zealand. With this alliance, the companies aim to offer end-to-end solutions in the Australian market and expand their medical services & customer base.
The pharmacovigilance market is bifurcated in terms of type, clinical trial phase, service provider, end-use, and region.
Based on the clinical trial phase, the phase 2 segment is expected to reach over $410 million by the end of 2032. This second stage of trials is conducted to evaluate the safety and efficacy of a drug candidate in a larger group of patients with the target disease or condition. The rising number of clinical trials worldwide is fueling the need for robust pharmacovigilance systems to monitor and ensure patient safety during these trials.
With respect to end-use, the pharmacovigilance market value from the medical device companies segment was over $2.5 billion in 2022. Pharmacovigilance service providers supply medical device safety profiles to companies, ranging from the processing and reporting of single adverse incidents through the withdrawal of products from the market as part of a Field Safety Corrective Action. The greater emphasis of regulatory bodies on post-market surveillance and safety monitoring of medical devices is bolstering product uptake.
Asia Pacific pharmacovigilance market is expected to exhibit an appreciable CAGR between 2023 and 2032, attributed to the availability of numerous outsourcing organizations. The increasing productivity, cost efficiency, and resource sharing are expected to drive regional demand for pharmacovigilance in the upcoming years. Additionally, the expanding population base with increased drug intake and healthcare demand are also complementing the regional market growth.